Adele F Holloway

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8240612/publications.pdf

Version: 2024-02-01

19	618	840119	794141
papers	citations	11	19
		h-index	g-index

19	19	19	1235
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential. Marine Drugs, 2015, 13, 2327-2346.	2.2	245
2	Changes in Chromatin Accessibility Across the GM-CSF Promoter upon T Cell Activation Are Dependent on Nuclear Factor ÎºB Proteins. Journal of Experimental Medicine, 2003, 197, 413-423.	4.2	68
3	Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and In Vivo. Journal of Cellular Physiology, 2016, 231, 688-697.	2.0	37
4	RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 2014, 14, 808.	1.1	35
5	GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements. Nucleic Acids Research, 2005, 33, 225-234.	6.5	33
6	Interplay between Transcription Factors and the Epigenome: Insight from the Role of RUNX1 in Leukemia. Frontiers in Immunology, 2015, 6, 499.	2.2	26
7	Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer. Prostate, 2015, 75, 723-734.	1.2	24
8	Functional Interaction between the HIV Transactivator Tat and the Transcriptional Coactivator PC4 in T Cells. Journal of Biological Chemistry, 2000, 275, 21668-21677.	1.6	22
9	DNA methylation changes following DNA damage in prostate cancer cells. Epigenetics, 2019, 14, 989-1002.	1.3	22
10	Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo. Oncotarget, 2016, 7, 46028-46041.	0.8	20
11	Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1. Leukemia Research, 2010, 34, 1203-1213.	0.4	17
12	Epigenetic regulation of the ITGB4 gene in prostate cancer. Experimental Cell Research, 2020, 392, 112055.	1.2	14
13	Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells. Journal of Cellular Physiology, 2018, 233, 3439-3453.	2.0	12
14	Genetic Determinants of Epigenetic Patterns: Providing Insight into Disease. Molecular Medicine, 2015, 21, 400-409.	1.9	10
15	Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses. Clinical Epigenetics, 2016, 8, 75.	1.8	10
16	The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1. Journal of Cellular Biochemistry, 2016, 117, 49-58.	1.2	7
17	Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation. Pathology, 2018, 50, 622-628.	0.3	7
18	Depletion of c-Rel from Cytokine Gene Promoters Is Required for Chromatin Reassembly and Termination of Gene Responses to T Cell Activation. PLoS ONE, 2012, 7, e41734.	1.1	5

#	Article	IF	Citations
19	A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer. Breast Cancer Research and Treatment, 2022, 192, 89-100.	1.1	4